The stocks of Boyd Gaming Corporation (NYSE:BYD) has been Initiated to Equal Weight by Barclays in its latest research note that was published on September 03. BYD was given a price target of $8, with other Wall Street analysts also giving their reports regarding the stock. The stock also received a Hold to Buy rating from Desjardins. This was contained in a research note published by the firm on August 16. The stock received a Market Perform to Outperform rating and a price target of $31 to $36 in Telsey Advisory Group’s research note that was published on July 31.
Boyd’s stock is covered by 14 analysts, with 13 of them rating the stock as Buy. It has been deemed to have strong buy by none of the analysts, 1 of them have rated it as a Hold while none of them rated it as sell. The situation was different a month ago when the stock was rated as a Buy by only 12 analysts. None of them rated it as strong buy with 2 of them recommended investors to Hold on to the stock. Meanwhile, none analyst(s) rated it as a sell. The above data shows that BYD has an average analyst rating of Buy.
BYD surged by $0.27 during the normal trading session on Thursday and reaching a high of $29.23 during the day while it closed the day at $28.67. The Boyd stock had a low trading volume of 0.97 million shares on that day, which is low compared to the average daily volume of 1.03M shares. BYD has also lost 3.79% of its value over the past 7 days. However, the stock has surged by 19.91% in the 3 months of the year. Over the past six months meanwhile, it has gained 14.36% while it has added 37.97% year-on date.
Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) jumped over 0.10 percent on Thursday. The company’s stock began trading at $72.17 above the previous closing price of $72.1, and finished the day at $70.71. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -4.45% from its 3 months high price. However, taking another look at CRSP will indicate that it is trading +99.41% away from its 90-day low. Looking at the bigger picture, the CRISPR Therapeutics AG stock has dropped by -4.45% from its 52-week high while it has surged by +218.23% from its 52-week low price.
On November 19, 2019 Bolzon Bradley J PhD, Director sold 42,000 shares of the company. The average price for that transaction was $67.41 per share, which meant that Bolzon Bradley J PhD earned $2,831,220.00 selling the stocks. The sale was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Director, CAGNONI PABLO J selling 7,500 shares of this stock on November 19, 2019. The average selling price for the stock was $62.00 per share, with the sold stock accruing $465,000.00. Following this transaction, the insider now holds 596,741 shares of the company, which is worth around $17,281,619.00.
Let us now take a quick look at the stock’s short, medium and long-term indicators. Composite Indicator shows that CRSP stock was rated as a Buy by TrendSpotter. Its short-term indicators reveal that CRISPR has a 20-day average volume of 1630210 shares. This has led to the CRSP price forecast being placed as a 100% Buy on an average basis. In the medium term, however, the CRSP stock has its 50-Day average volume of 1046334 shares, with the indicators also rating it as a 100% Buy. Finally, in the long-term, the CRSP stocks have a 100-Day average volume of 758802 shares, with the long-term indicators rating the stock as just 100% Buy. Looking at the three indicators, the CRSP stock has been set on a 1 Buy rating.
CRISPR has around 630 Million cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $80 Million. The CRISPR stock is bringing in revenue of over 12 months, which is roughly 213 Million. Despite all that, CRISPR Therapeutics AG is seeing things progressing very much as their y-o-y quarterly revenue surged by 0.84%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 91.46%. This figure is better than the company’s 20-day Raw Stochastic average which currently stands at 87.4%. Over the past 20 days, CRISPR’s Stochastic %K stood at 92.38% while its Stochastic %D was revealed to be 90.61%.